Patient-Reported Outcomes for Determining Prognostic Groups in Veterans With Advanced Cancer

• Published in: Journal of pain and symptom management 2015-09, Vol.50 (3), p.313-320
• Main Authors: Chang, Victor T., MD, Scott, Charles B., PhD, Gonzalez, Melanie L., MPH, Einhorn, Jan, RN, Yan, Houling, BS, Kasimis, Basil S., MD, DSc
• Format: Article
• Language: English
• Subjects: Aged; Anesthesia & Perioperative Care; Female; Functional Assessment of Cancer Therapy; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Memorial Symptom Assessment Scale-Short Form; Neoplasms - diagnosis; Pain Medicine; Patient Outcome Assessment; Prognosis; Proportional Hazards Models; Prospective Studies; Quality of Life; recursive partitioning algorithm; Self Report; survival; symptoms; Veterans - psychology
• ISSN: 0885-3924; 1873-6513
• DOI: 10.1016/j.jpainsymman.2015.03.016

Abstract Context Physicians overestimate survival in patients with advanced cancer. Patient-reported outcomes could provide another way to estimate survival. We previously reported four prognostic groups based on Karnofsky Performance Status, Functional Assessment of Cancer Therapy physical well-being subscale, and Memorial Symptom Assessment Scale-Short Form physical symptom distress subscale scores. Objectives To determine the validity of these four prognostic groups. Methods We performed prospective surveys. Data from a total of 880 Veterans Affairs Medical Center patients, 417 in the First Cohort and 463 in the Validation Cohort, were analyzed. Both inpatients and outpatients were prospectively recruited in Institutional Review Board-approved studies from August 1999 to September 2009. Survival was measured from the date of entry until death or December 1, 2009. Patients completed self-assessments with the Functional Assessment of Cancer Therapy and Memorial Symptom Assessment Scale-Short Form. Analysis of variance was used to test differences between groups in continuous variables; a generalized Wilcoxon test was used for differences between groups for survival. Results The average age in the Validation Cohort was 66.5 years and 98% were men. The majority of patients had metastatic cancer (90%), with lung (28%) and prostate (26%) cancers being predominant. The median Karnofsky Performance Status was 70. Median survival was 33, 46.5, 124, and 209.5 days for the four prognostic groups ( P